@article{oai:kanazawa-u.repo.nii.ac.jp:00014491,
 author = {Ishiyama, Ken and Takami, Akiyoshi and Kanda, Yoshinobu and Nakao, Shinji and Hidaka, Michihiro and Maeda, Tetsuo and Naoe, Tomoki and Taniguchi, Shuichi and Kawa, Keisei and Nagamura, Tokiko and Tabuchi, Ken and Atsuta, Yoshiko and Sakamaki, Hisashi},
 issue = {3},
 journal = {Leukemia},
 month = {Mar},
 note = {We have recently reported that the outcome of acute myeloid leukemia (AML) patients with t(6;9)(p23;q34) who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) was comparable to that of patients with a normal karyotype. We performed a further analysis regarding the prognostic factors for t(6;9)(p23;q34) AML patients who underwent a HSCT. Seven pediatric patients and 57 adult patients, transplanted between 1996 and 2007, were assessed in this study. The overall survival (OS) of the pediatric patients tended to be better than the OS of the adults, although there were no statistically significant differences. The present study focused on the adult patients revealed that the disease status at HSCT was the sole prognostic factor affecting the OS identified in the univariate analysis. A multivariate analysis showed that the disease status at HSCT and M2 in the FAB classification were extracted as the significant variables affecting the OS. The patients who were not in remission at HSCT and had non-FAB-M2 showed a poorer outcome; 6 deaths in the 9 patients were due to a relapse of the AML. These findings suggest that novel therapeutic approaches might be needed for patients with these poor prognostic factors., 発行後6か月より全文公開},
 pages = {461--464},
 title = {Prognostic factors for acute myeloid leukemia patients with t(6;9)(p23;q34) who underwent an allogeneic hematopoietic stem cell transplant},
 volume = {26},
 year = {2012}
}